Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 14/20 | 0.51 |
| ▸ | RAB9A | P51151 | 14/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.50 |
| ▸ | RELA | Q04206 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982643 | 0.98 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL5459716 | 0.96 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4985077 | 0.94 | NPC1 (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30226379 | 0.84 | ADRA2A (0.50) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4984078 | 0.84 | TRPV1 (0.60) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13785779 | 0.83 | NPC1 (0.54) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13017203 | 0.83 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3783652 | 0.83 | ADRA2A (0.55) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16692423 | 0.80 | SMN1; SMN2 (0.46) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3771009 | 0.79 | PLAU (0.57) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | SCION PHARMACEUTICALS, INC, A DELAWARE CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-6787569-B1 | INHIBITORS OF NEUROTRANSMITTER (E.G., GLUTAMATE) RELEASE FROM ISCHEMIC NEURONAL CELLS; N,N-DISUBSTITUTED GUANIDINES; NEUROLOGICAL CONDITIONS SUCH AS EPILEPSY, NEURODEGENERATIVE CONDITIONS AND/OR NERVE CELL DEATH FROM STROKE OR HEART ATTACK | CAMBRIDGE NEUROSCIENCE, INC. | 2004-09-07 | — | — | US | disclosed |
| US-6174924-B1 | Therapeutic guanidines | CAMBRIDGE NEUROSCIENCE, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6143791-A | NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | GAP43, NLN, HTT | ADRA2A 808/4885NPC1 418/4885RAB9A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.